# Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype

> **NCT07282210** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Biossil Inc.** · enrollment: 105 (estimated)

## Conditions studied

- Sickle Cell Disease
- Sickle Cell Anaemia
- Sickle Cell Anemia

## Interventions

- **DRUG:** Senicapoc
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07282210
- **Lead sponsor:** Biossil Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2028-11
- **Final completion:** 2029-01
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282210, "Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07282210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*